• Kobayashi K, Kanda H, Shimazaki R, Murata TKobayashi M. Economic Evaluation of Egfr Control In Patients With Chronic Kidney Disease In Japan. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 6, 2017.

  • Noto S, Igarashi A, Shiroiwa T, Fukuda T, Ikeda S, Moriwaki K, Saito S, Shimozuma K, Ishida H, Kobayashi M. Reliability And Validity Of Two Proxy Versions Of EQ-5D-5L In Japan. ISPOR 20th Annual European Congress Glasgow, Scotland. Research Poster Presentations. Nov 7, 2017.

  • Noto S, Izumi R, Moriwaki K, Shiroiwa T, Igarashi A, Fukuda T, Ikeda S, Saito S, Shimozuma K, Ishida H, Kobayashi M. Comparison Between Eq-5d And Hui In Japanese Population Norms. ISPOR 20th Annual European Congress Glasgow, Scotland. Nov 4-8, 2017.

  • Yamabe K, Inoue S, Kuwabara H, Kobayashi M. Cost-Effectiveness Analysis For Treatment Of Parkinson’s Disease: A Systematic Review. ISPOR 20th Annual European Congress Glasgow, Scotland. Nov 4-8, 2017.

  • Noto S, Sengoku A, Nomi M, Murata T, Kato S. Relationship between bowel dysfunction and health-related QOL in patients with spinal cord injury. The 51st Japanese Cvvupational Therapy Congress & Expo. 22-24 September, 2017.

  • Seno A, Yin C, Metz L, Ghosh SK, Murata TKobayashi M. The treatment effect on early stage hepatocellular carcinoma in Japanese population: Literature review. ISPOR 22nd Annual International Meeting Boston USA. Research Poster Presentations. May 22, 2017.

  • Okumura H, Inoue S, Naidoo S, Holmstrom S, Akaza H. Cost-effectiveness analysis of enzalutamide for patients with pre-metastatic castration-resistant prostate cancer. The 105th Annual Meeting of the Japanese Urological Association. April 21-24, 2017.

  • Nitta K, Sugiyama K, Wajima R, Tachibana M, Inoue S, Daitou T, Kurashima H. Study on the forecas of risk of suffering severe vision disability with primary open angle Glaucoma(broadly defined). The 121st Annual Meeting of the Japanese Ophthalmological Sciety. April 6-9, 2017.

  • Wang F, Murata T, Izumi N, Kida M, Horblyuk R, Terayama Y. Bleeding risk among Japanese non-valvular atrial fibrillation patients initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin in the real world. American College of Cardiology. March 18, 2017.

  • Kobayashi M. The trial intordoction of cost-effectiveness evoluation and future prospects in japan. 4th seminar of the center of pharmacoeconomics and QOL research at Niigata University of health and welfare. Niigata University of health and welfare, Niigata, Japan. 4th Mar, 2017. (in Japanese).


Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis

and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA